Courageous. Focused. Passionate.

Harnessing the Power of Nature With Precision Science™

Cancer continues to inflict devastating consequences worldwide. Bexion is committed to conquering cancer and to deliver on our commitment, we have assembled a world class leadership team to advance our innovative, targeted cancer therapy platform. Targeted therapy brings significant potential to the fight against cancer and we are relentless in our pursuit to realize this potential.

banner-info
Home2020-01-20T09:17:26-05:00

– Our Platform

An innovative, targeted approach to treating cancer

Our treatment specifically targets unique features of cancer cells, including externalized phosphatidylserine and tumor cell lysosomes by utilizing a small lysosomal protein known as Saposin C.

Learn More

– Our Pipeline

A Pipeline-in-a-Product asset with potential for multiple indications

BXQ-350 is the foundation of our pipeline. Early clinical results have shown a strong safety and tolerability profile.

Learn More

– clinical trials

Update

Our clinical trials are regulated by the Food and Drug Administration (FDA) in the United States and by similar regulatory agencies worldwide.

Learn More

Resources

Bexion Resources

Resources

Learn More
View All Resources

News

    Press Release

    Bexion Pharmaceuticals Announces the Addition of Olivia F. Kirtley to Board of Directors

    February 22, 2021

    FOR IMMEDIATE RELEASE Covington, KY February 22, 2021 Bexion Pharmaceuticals, Inc. announced today that it has added Olivia F. Kirtley to its Board of Directors. Ms. Kirtley, a Certified Public Accountant and Chartered Global Management Accountant, is a business consultant on strategic, risk and corporate governance issues. She brings to Bexion extensive experience as ... Read More

      Press Release

      Bexion Pharmaceuticals Announces Database Lock in Phase 1 Trial of BXQ-350

      December 10, 2020

      FOR IMMEDIATE RELEASE Covington, KY, December 10, 2020               Bexion Pharmaceuticals, Inc., a clinical stage biotech company focused on the discovery and development of life-changing treatments by leveraging the lysosome's roles in solid tumors and cell death with an initial focus on cancer, announced today the database lock for the Phase 1 study of BXQ-350 in adult patients ... Read More

      View All Media